Latest Commercialization News

Greenvale Energy has successfully scaled its Alpha Torbanite Project test program by 40 times and commenced bulk sample production aiming for commercial bitumen certification.

Anson Resources and POSCO Holdings have advanced their collaboration on the Green River Direct Lithium Extraction demonstration plant, with POSCO’s investment decision timeline pushed to early 2026. The partnership signals a strategic move to secure North American lithium resources and commercialize cutting-edge extraction technology.

CTI Logistics Limited anticipates a significant 55% increase in profit before tax for the half year ending December 2025, driven by robust revenue growth and operational improvements in Western Australia.

Eastern Gas Corporation Limited, a new ASX-listed subsidiary of Pure One Corporation, has lodged a Replacement Prospectus to raise $5.5 million for advancing its Queensland gas projects, targeting commercial production through horizontal drilling and fracture stimulation.

Horizon Oil and its joint venture partners have signed a binding Letter of Intent with Northern Territory’s Power and Water Corporation to fast-track drilling of two new wells at Mereenie, aiming to secure long-term gas supply agreements through 2034.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

HyTerra Limited has appointed Riley Kemp as its new CEO, aiming to accelerate growth and strengthen its position in the emerging geologic hydrogen sector.

Resolution Minerals appoints Dr Adam Roper as Chief Metallurgist to advance antimony, tungsten, and gold processing at its Idaho Horse Heaven Project, aligning with US defense supply chain goals.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Fortifai Limited introduces Nol8, a breakthrough platform that processes data in real time with millisecond latency, promising to transform industries reliant on massive data flows.